Boussard & Gavaudan Investment Management’s Avidity Biosciences RNAM Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,384	Closed	-$221K	–	109
2025 Q4	$221K	Buy	+3,384	New	+$219K	0.02%	80

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Boussard & Gavaudan Investment Management's RNAM Position: Q1 2026 in Review

Boussard & Gavaudan Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 328,204 shares — an estimated $23.7M sold.

Boussard & Gavaudan Investment Management first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $23.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Boussard & Gavaudan Investment Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Boussard & Gavaudan Investment Management sold 328,204 Avidity Biosciences shares in Q1 2026, an estimated $23.7M.
Boussard & Gavaudan Investment Management first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
Boussard & Gavaudan Investment Management's Avidity Biosciences position peaked at $23.7M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.